Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30999375 | 0.94 | CTSC (0.50) | OPRK1LTA4HCTSC | |
| SCHEMBL29683939 | 0.91 | OPRK1 (0.53) | OPRD1OPRM1OPRK1CTSCREN | |
| SCHEMBL29684030 | 0.87 | OPRD1 (0.48) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30053122 | 0.85 | OPRD1 (0.60) | OPRD1OPRM1OPRK1LTA4HCTSC | |
| SCHEMBL31479792 | 0.85 | OPRD1 (0.60) | OPRD1OPRM1OPRK1LTA4HCTSC | |
| SCHEMBL30064554 | 0.84 | MMP1 (0.51) | OPRK1CTSCREN | |
| SCHEMBL6811341 | 0.83 | OPRD1 (0.60) | OPRD1OPRM1OPRK1LTA4H | |
| SCHEMBL31096839 | 0.83 | MME (0.56) | OPRD1OPRM1OPRK1LTA4HCTSC | |
| SCHEMBL6811347 | 0.83 | OPRD1 (0.60) | OPRD1OPRM1OPRK1LTA4H | |
| SCHEMBL31400267 | 0.83 | ACACB (0.46) | OPRK1CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993629-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20220106355-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993629-B2 | Method for producing peptide compound | VIP, NGLY1, IAPP | OPRD1 2975/4885OPRM1 2853/4885OPRK1 2829/4885 |
| US-20220106355-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, NGLY1, IAPP | OPRD1 2975/4885OPRM1 2853/4885OPRK1 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.